The partner enablement kit
Everything you need to publish, and nothing you have to ask us for.
Twenty-two message-matched destinations, pre-cleared copy for every one of them, five embeddable widgets that keep your post accurate after you have stopped thinking about it, and a link builder that writes the disclosure and checks your own wording before you can copy it. Public, ungated, free to read whether you ever apply or not.
Clinician-supervised · third-party tested · compounded, not FDA-approved · WAITLIST MODE: consults open soon
Start here
Sixty seconds to your first compliant link.
Four steps. Nothing to download, nothing to request, no approval queue.
- 01
Paste your partner ID
It stays in this browser and hydrates every link, UTM string and embed snippet on this page. Leave it blank and everything renders with a visible YOUR_ID placeholder.
- 02
Pick a lane
Five lanes, matched to the need-states the site is actually built around. Pick the one your audience already talks to you about.
- 03
Grab one destination kit
Reader, angle, four channel hooks, say-this / never-this, the compliant CTA, your tagged link and the exact disclosure. One card, nothing to assemble.
- 04
Publish with the disclosure
Every copy button hands you the disclosure with the copy. You cannot lift a hook without lifting the line that makes it legal.
The lane router
Five lanes. Pick the one your audience already asks you about.
Each lane has a door — the page to send cold traffic to when you do not have a specific symptom to match. Selecting a lane filters the destinations below.
The 22 destinations
Twenty-two pages, twenty-two complete kits.
Every kit carries the same structure, generated from one data file: who lands there, the belief the page changes, four channel hooks, the say-this and never-this pair, the compliant CTA, your tagged link and the disclosure. No status is written into any kit — adjacency warnings read the tracker live.
Hubs and education
Twenty more destinations, abbreviated.
Same perimeter, less scaffolding. Each carries the angle that works and the one rule that page attracts trouble on.
The full catalogue, one page, with each entry's own status.
Hub page — never summarise multiple molecules into one status sentence.
The route, the review, the pricing, no euphemism.
No performance claims of any kind.
The door for the whole women's lane.
Reclamation framing, never vanity, never before/after.
Two doors: full-dose and the microdose route.
Never describe either door by amount.
Measurement before molecule.
“Reverse aging” is banned outright.
Where the demand is unsellable and honest.
Every recovery peptide named here is gated. Status card only.
Plain clinical language beats every euphemism.
PT-141 is gated; do not bring it into the hook.
The most-searched, least-sellable name in the category.
Education only. No availability language in any form.
The second half of the recovery search volume.
Education only. No availability language in any form.
Topical and injectable are different regulatory pathways.
Never merge the two forms into one status.
A green-verdict molecule with real provenance.
Withdrawn in 2008 for commercial reasons — say so accurately or not at all.
The comparison the forums argue about, graded.
Both are gated. Compare evidence, never access.
The dated regulatory board. The strongest link asset we have.
Never summarise the board into one sentence.
Our dated record, with primary sources.
Point at journalism; do not restate a verdict from memory.
Get told when a verdict changes.
Education and waitlist only.
Fifty-four monographs, no dosing in any of them.
No dosing fields exist. Never add one in your own summary.
Combinations, graded, with the weak evidence labelled.
A stack is not a prescription. Never publish one as instructions.
The pharmacy-category distinction, explained once, properly.
Pure education. Nothing here may read as an offer.
A checklist that names nobody, including where we fail it.
Do not turn it into a competitor attack.
Method, not outcome. The honest framing does the persuading.
Evidence grade is never a traffic-light colour.
The widget library
Five embeds. All of them read the live feed.
One line of code each, no key, no account. They read our public CC BY 4.0 feeds on every page view, which is the whole point: your post cannot go stale and cannot overclaim, even years after you wrote it. None of them contains a price, a dose, or an availability field for a gated molecule.
The link builder
It writes the link, the disclosure, and the warning.
Pick a destination and a channel. You get the tagged URL on the published UTM convention, the HTML with rel="sponsored" already on it, the exact disclosure for that channel, and the say-this / never-this pair for that page. Type your own anchor text and it is checked before you can copy anything.
https://peptos.life/weight-at-45-wont-move?partner=YOUR_ID&utm_source=written&utm_medium=affiliate
<a href="https://peptos.life/weight-at-45-wont-move?partner=YOUR_ID&utm_source=written&utm_medium=affiliate" rel="sponsored">See what a clinician-built path actually looks like</a>
Disclosure: paid partnership with Peptós.LIFE. I earn a commission on referrals through my link.
Above the link and above the fold — before the reader has to click "see more".
- Perimenopause changes the metabolic baseline. That is a documented physiological shift, not a discipline problem.
- A clinician reviews your history and labs before recommending anything at all.
- Compounded medications used in this category are not FDA-approved.
- Any figure of pounds lost, or any timeframe attached to a result.
- “Finally works” / “the fix” / any framing that makes the page a promise.
- Naming a specific medication as something she can get today.
?partner={id}&utm_source={channel}&utm_medium=affiliate&utm_campaign={campaign}
One convention, enforced by the builder, so reporting is clean from day one. partner carries attribution site-wide; the UTM triple is for your own analytics.
The catalyst calendar
Publish two weeks before the date, not the day after.
Regulatory dates create search spikes. The traffic goes to whoever was already ranking when the spike arrived. These are the events we can see coming, with the date to publish by and the angle that is already cleared.
What the second advisory batch is reviewing, and why a recommendation would still not be approval.
The six recommended in July 2026 and what rulemaking actually has to do before anything changes.
What the shortage-exception pathway is, and why it is not the same as approval.
One year on: six recommended, one declined, and what has and has not changed since.
Dates track the tracker and move when it moves. Subscribe at /fda-tracker-alerts and you will hear about a change before your comments section does.
Playbooks
The unsellable-demand play, and four others.
The unsellable-demand playbook. BPC-157 and TB-500 are among the most-searched names in this entire category and among the least sellable — both are gated, and neither can be described as obtainable by anyone, including us. Most affiliates therefore skip them, which is why the volume sits there unclaimed.
The play: take the query, send it to the symptom page rather than a product page, embed the live status card so the post stays accurate without you, and let attribution do the rest. Your tag holds site-wide for the cookie window — the reader who arrives on an unsellable molecule and subscribes to something else entirely, inside the window, still credits you. That deferred attribution is the whole reason this traffic is worth writing for.
Steal this post
One publish-ready structure per lane.
Most approved partners never launch because the first asset is the hard part. Here is the first asset, three formats, already inside the perimeter. Edit into your own voice; do not edit out the disclosure timing.
Women's longevity
Blog post
800 words · “Nobody told me perimenopause would change my body composition” — open on the reader's own sentence, name the physiological shift, describe what a proper intake asks, close on the clinician gate. No molecule named above the fold.
Video script
60s · 0–3s: on-screen “#ad — paid partnership with Peptós.LIFE” + spoken. 3–15s: the dismissal she has already heard. 15–40s: what actually changed. 40–55s: what a proper intake asks. 55–60s: the compliant CTA.
Email sequence
5 emails · (1) “That's just menopause” is a description, not a diagnosis · (2) What a proper intake asks · (3) Why hormonal context changes the plan · (4) Named clinicians, third-party testing, published pricing · (5) The founding list, plainly.
Metabolic / weight
Blog post
800 words · “Everyone is selling the same molecules” — the commodity argument, then the path argument: clinician, monitoring, maintenance phase, all-in pricing. Compounded-not-FDA-approved stated in the body, not a footnote.
Video script
60s · 0–3s: disclosure on screen and spoken. 3–12s: three providers, three first-month prices. 12–35s: what month four costs and why nobody shows it. 35–55s: what to ask any provider. 55–60s: CTA.
Email sequence
5 emails · (1) Ask what month four costs · (2) The maintenance phase nobody sold you · (3) Compounded is not FDA-approved, and what that means · (4) How to read a provider's pricing page · (5) The founding list.
Recovery
Blog post
800 words · “The recovery peptide threads leave out the only part that matters” — evidence grade and regulatory status as two separate questions, with a live status embed for each molecule named. Zero availability language throughout.
Video script
60s · 0–3s: disclosure. 3–15s: the forum claim. 15–40s: what the July 2026 recommendation did and did not do. 40–55s: where to check the current position yourself. 55–60s: CTA to the tracker.
Email sequence
5 emails · (1) A recommendation is not an approval · (2) Evidence grade, explained · (3) The two signals and why they disagree · (4) How to check a status yourself · (5) Get told when it changes.
Longevity / energy
Blog post
800 words · “There is no single longevity stack” — method over shopping list, with weak evidence labelled weak. The grading method is the persuasion.
Video script
60s · 0–3s: disclosure. 3–15s: half your stack has one small trial behind it. 15–40s: how to grade a claim. 40–55s: measurement before molecule. 55–60s: CTA.
Email sequence
5 emails · (1) Measurement before molecule · (2) How we grade, and where we say the evidence is thin · (3) What biological age can and cannot tell you · (4) Reading a monograph properly · (5) The founding list.
Sexual health
Blog post
800 words · “The awkward part is the marketing, not the medicine” — plain clinical language, the intake as medical screening, published pricing, no euphemism anywhere.
Video script
60s · 0–3s: disclosure. 3–15s: why the category's marketing is embarrassing and the medicine is not. 15–40s: what the clinician actually reviews. 40–55s: how to tell a legitimate provider. 55–60s: CTA.
Email sequence
5 emails · (1) Plain language, no euphemism · (2) What the intake questions are for · (3) The clinical difference between the two medicines · (4) Published pricing · (5) The founding list.
Which page for which question
Reader question in, destination out.
The biggest earnings killer in affiliate marketing is sending everyone to the homepage. Match the question to the page and the same traffic converts several times better.
- Pick one lane. Not three. The partners who ship pick one.
- Publish one asset from the steal-this-post library for that lane, edited into your own voice inside the perimeter.
- Embed one live status card on the molecule your audience names most — that is the asset that keeps earning after you stop editing.
- Set one alert at /fda-tracker-alerts so a verdict change reaches you before it reaches your comments.
The queries our 22 destinations already rank for, and the ones they do not, published at the JSON twin under keyword_gaps. Write the complementary article and link in — a partner ranking a supporting page is worth more to both of us than a partner competing with ours for the same result.
One pre-rendered, on-brand image per destination at /og/{slug}.png, or the lot in one zip at /og/peptos-og-pack.zip. Creators reuse whatever image is easiest to find, so ours is the easiest to find. Not shipped yet — the routes are reserved.
/fda-tracker-news/rss.xml — our dated newsroom as a feed you can auto-post from, partner-tagged. Add ?partner={id} and every syndicated link carries your attribution. Not shipped yet — the route is reserved. Until then, subscribe at /fda-tracker-alerts.
Drag Peptós check to your bookmarks bar, or copy it above and save it as a bookmark by hand. Run it on any draft and it returns which of the six rules the copy breaks. Same banned-terms list as the link builder, in your own drafting tool.
No data yet. Consults are not open, so there is nothing honest to put here. This board fills in once there is a real distribution to show, and we will publish it rather than describe it.
What counts right now
The programme is honest about where it is.
Consults open soon. Until they do, the qualifying action is a founding-list signup at /waitlist, and your tag holds site-wide for the cookie window — including on the tracker and Knowledge Base pages, not just the funnel. The flat CPA per qualified new member applies from first subscription once consults open.
Rates are set in your partner agreement. We are not publishing a number we have not set, so every commission figure on this site reads $[N] until it is real. Nothing on peptos.life is transactable today, and nothing on this page may be written as though it were.
The perimeter, condensed
Six rules. 27 molecules nobody may promote as obtainable.
The count is generated from tracker data at page load, not typed here, so it cannot drift. The full standard — every rule with its worked example, the live do-not-promote table, the FTC copy and the prohibited-traffic list — is at /partners/compliance. Read it once properly; this card is a reminder, not a replacement.
Here is where its FDA status actually stands.
It's finally back — link in bio.
Removed from Category 2 in April 2026 — not the same as lawful to compound.
Peptides are legal again.
Compounded semaglutide is not FDA-approved.
FDA-approved weight-loss medication.
An average across a trial population, not a prediction for you.
Lose 20%, guaranteed.
A clinician sets any dose after reviewing your history.
Anything with an amount, a unit or a schedule in it.
Six of seven recommended in July 2026; a recommendation starts rulemaking.
The FDA just approved BPC-157.
Availability
Saying or implying a gated molecule can be obtained.
Legality
Calling a peptide legal or illegal as a flat state.
FDA approval
Describing a compounded product as FDA-approved.
Dosing
Any amount, unit, schedule or “what I take”, in any framing.
- A disclosure or link-attribute failure gets one correction window. Uncorrected, it becomes a termination.
- Everything else is a conversation first — most problems are a caption written quickly, not bad faith.
- Anyone can report a violation, partner or not, anonymously. The full ladder is on the standard.
Changelog
What changed in the kit, and when.
New destinations, changed verdicts, retired angles. If you used a live embed you are already covered; if you used a screenshot, this is where you find out it needs replacing. Subscribe at /fda-tracker-alerts.
- Toolkit published: 22 destination kits, five widgets, the link builder and the compliance validator.
- Tracker resynced after the PCAC close. Every kit's adjacency warning re-derived; no kit copy changed, because no kit hard-codes a status.
- PCAC concluded: six of seven recommended, DSIP declined. All seven verdict dots remain amber.
- Retired every “decision expected” angle — the decision was advisory and rulemaking is pending.
Execution questions
How to ship, not how the programme works.
Programme terms, commissions and eligibility are on /partners.
Do I need approval before I publish?
No. Everything on this page is pre-cleared. Use the hooks, the say-this lines and the compliant CTA as written and you are inside the perimeter. Write your own anchor text and the link builder will check it before you copy it.
Can I edit the hooks?
Yes, within the perimeter. The six rules on the compliance standard govern, not these exact sentences. If your edit adds an availability, legality, FDA-approval or dosing word, the validator will catch it — paste it in before you publish.
What am I actually being credited for right now?
A founding-list signup at /waitlist. Consults are not open, so nothing is transactable. Your tag holds site-wide for the cookie window, including on the tracker and Knowledge Base pages, and the flat CPA applies from first subscription once consults open.
Why is there no commission number on this page?
Because we have not set one, and publishing a rate we have not set would be the exact kind of claim this whole programme tells you not to make. Rates are set in your partner agreement.
The tracker changed a verdict. Do I have to update my old posts?
If you used a status embed, no — it re-reads the feed on every page view and updates itself. If you used a screenshot, yes, and this is the argument for using the embed. Subscribe at /fda-tracker-alerts and you will be told when something moves.
Can I write about BPC-157 at all?
Yes, extensively. You may explain what it is, what the evidence says, and exactly where its regulatory status stands. You may not say, imply, hint or joke that it can be obtained. The status card is the safest way to reference it, because it renders the current position rather than your memory of it.
Do the widgets need an API key?
No. They read public CC BY 4.0 feeds. Attribution and a link back are the licence terms. If the feed is unreachable the widget degrades to a plain branded link rather than rendering anything stale.
Can I run paid search?
Non-brand terms only. Bidding on our name, trademarks, or close misspellings ends the relationship. The full prohibited-traffic list is on the compliance standard.
Last reviewed · every molecule status on this page is read from tracker data at page load, never authored here · machine-readable twin at /partners/affiliate-toolkit.json · Peptós.LIFE · Not medical advice.